Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22239262 | 0.92 | HRH3 (0.42) | HRH3GRIN2BGRIN1 | |
| SCHEMBL18629674 | 0.80 | GRIN2B (0.60) | HRH3GRIN2B | |
| SCHEMBL24866090 | 0.79 | GRIN2B (0.66) | GRIN2B | |
| SCHEMBL22239313 | 0.79 | HRH3 (0.39) | HRH3CYP1A2CYP2D6EPHX2 | |
| SCHEMBL24271019 | 0.79 | HRH3 (0.42) | HRH3CYP1A2CYP2D6 | |
| SCHEMBL20858821 | 0.79 | HRH3 (0.39) | HRH3CYP1A2CYP2D6 | |
| SCHEMBL29036781 | 0.78 | CYP1A2 (0.63) | HRH3CYP1A2CYP2D6ESR1ESR2 | |
| SCHEMBL24866256 | 0.77 | GRIN2B (0.62) | GRIN2BGRIN1 | |
| SCHEMBL24136402 | 0.77 | GRIN2B (0.39) | GRIN2BGRIN1 | |
| SCHEMBL22239299 | 0.76 | ESR1 (0.43) | HRH3ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023233357-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| EP-3683207-B1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3683207-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |